Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
Abstract Background Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was granted approval by the European Medicines Agency (EMA) for the treatment of Renal Cell Carcinoma in adults....
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2022-04-01
|
| coleção: | BMC Cancer |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12885-022-09475-7 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|